The Latest Cardiac and Vascular News
BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective ALAMEDA, Calif., Oct. 20, 2026 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) […]
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical […]
MIAMI, Oct. 21, 2026 /PRNewswire/ — Resolve Therapeutics, LLC, a clinical-stage biotechnology company developing nuclease-Fc fusion proteins designed to degrade pathogenic extracellular nucleic acids, today announced two e-posters featuring preclinical data on its RNase-Fc fusion protein…
VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium today announced the first site activation and first patient enrollment in the Globe Registry: Globe® Pulsed Field System Registry for Treating Patients with Symptomatic Atrial Fibrillation. The registry marks an important milestone in the continued commercial adoption of the Globe System following positive physician experience, strong procedural outcomes, and a growing body of evidence supporting the system’s unique integrated mapping and ab
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the DIRECT study in The Oncologist, in
BOSTON–(BUSINESS WIRE)– #510k–Elucid has received FDA 510(k) clearance of FFR-IQ™, its software for noninvasive estimation of fractional flow reserve from coronary CT angiography.
SAN DIEGO–(BUSINESS WIRE)– #Medtech–Vektor Medical, a medical technology company advancing the treatment of cardiac arrhythmias through its non-invasive, AI-based arrhythmia analysis technology, vMap®, today announced the completion of patient enrollment in its IMPRoVED-AF randomized clinical study and the appointment of Brandon Allen as Senior Vice President of Sales. Together, these milestones mark important progress in Vektor’s efforts to expand commercial adoption of vMap and strengthen the clinica
SUNNYVALE, Calif.–(BUSINESS WIRE)–EBR Systems, Inc., developer of the world’s only left ventricular endocardial pacing (LVEP) system for heart failure, announces the appointment of Robert C. Canby, MD, as Chief Medical Officer. Key Highlights Robert Canby, MD, appointed Chief Medical Officer is a board-certified cardiac electrophysiologist who brings extensive experience across clinical practice, physician education, cardiovascular research, and medical device innovation. Dr. Canby practices
Financing Strengthens Balance Sheet and Supports Continued Product Innovation and Commercial GrowthWEST JORDAN, Utah, Oct. 20, 2026 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced that it has entered into a $100 million senior secured debt facility with Trinity Capital Inc., a leading provider of flexible capital solutions for innovative, growth-stage to lower middle market companies across the United States and Europe. Route 92 Medical has developed an integrated neurovascular platform that combines access, delivery, and control in a cohesive system, enabling clinicians to reach treatment sites reliably and efficiently. Tenzing® delivery catheters are foundational to the Route 92 platform, enabling atraumatic, precise, and controlled navigation through complex neurovascular anatomy. All Route 92 access and aspiration catheters are powered by custom-sized Tenzing delivery catheters and are size-matched to the vessels they access. Route 92 has also developed Monopoint®, the only mono-axial neurovascular platform, featuring a streamlined telescoping design that advances from a single point of control to simplify neurovascular intervention. “Entering into this financing with Trinity Capital is an important step for Route 92 as we execute on our growth strategy,” said Raj Denhoy, Chief Financial Officer of Route 92 Medical. “This facility gives us additional financial flexibility to support the strong demand we are seeing for our products. Trinity’s understanding of the medical technology sector and their confidence in our technology, commercial momentum, and long-term vision make them a valuable partner as we work to transform the treatment of neurovascular disease.” Route 92’s portfolio of advanced neurovascular catheters includes the FreeClimb® 46, 54, 70, and 88 systems, as well as the HiPoint® 70 and 88 systems, which feature Monopoint. HiPoint 88 is the first super-bore aspiration system with FDA clearance for direct aspiration of large vessel occlusions (LVOs) in acute ischemic stroke. The most recent addition, FreeClimb 46 with Tenzing 4, offers a differentiated tool for navigating more distal and smaller anatomies. Route 92’s catheters and systems are covered by a portfolio of more than 200 issued patents in the U.S. and international jurisdictions. About Route 92 Medical, Inc.Route 92 Medical is on a mission to improve outcomes for patients undergoing neurovascular intervention through cutting-edge engineering, innovative product design, and revolutionary procedural change. Founded by physicians, the company collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success. For more information, visit www.r92m.com or follow the company on LinkedIn. CONTACT: Contacts:
For media:
Gwen Gordon
Gwen@gwengordonpr.com
Philips cardiology informatics at TCT
Philips cardiology informatics at TCT
October 20, 2026 Advanced reporting and workflow capabilities developed by MediReport are expected to complement Philips’ cardiovascular informatics portfolio and support its evolution toward a more connected, AI-enabled and cloud-ready cardiovascular experience. Amsterdam, the Netherlands – October 20, 2026 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how advanced reporting and workflow capabilities developed by MediReport are expected to complement its cardiovascular informatics portfolio and support its broader Integrated Diagnostics vision ahead of Transcatheter Cardiovascular Therapeutics (TCT) 2026. Philips brings together expertise in diagnostic and interventional cardiology, image-guided therapy and informatics to support cardiovascular care, from diagnosis through intervention and follow-up. As part of its presence at TCT, Philips will showcase innovations that support clinical confidence, streamline workflows and make meaningful information easier to access, while engaging with customers and clinical leaders on opportunities to better connect diagnostic and interventional care. Cardiovascular teams often work across separate imaging, hemodynamic, documentation and reporting systems. This can require repeated data entry and delay access to the complete clinical information needed for procedure reporting, coding and follow-up. In Philips’ Future Health Index 2025: Cardiology Snapshot, 79% of cardiac care professionals surveyed reported losing clinical time because patient data was incomplete or inaccessible. Almost half of this group reported losing more than 45 minutes per shift [1]. These findings underline the need to make clinical information easier to capture, access and reuse across the care pathway. Following the acquisition of MediReport, Philips expects to strengthen its cardiovascular informatics capabilities. MediReport 360 supports structured cardiovascular documentation and real-time reporting at the point of care, with guided workflows before, during and after procedures. It enables health systems to capture clinical information once and reuse it across physician and nursing reports, coding, registries, analytics, charge capture and follow-up. MediReport’s technologies support cloud and on-premises deployment, with vendor-neutral interfaces to imaging systems, hemodynamic systems and hospital IT. This expected enhancement would build on Philips’ existing cardiology informatics portfolio, including Cardiovascular Workspace for image and information management, with cloud deployment available in North America; Ultrasound Workspace for ultrasound review, analysis and reporting; and interventional solutions supporting cath-lab information management and hemodynamic workflows. “Clinicians need technology that fits the way they work and gives them more time for patient care”, said Madhuri Sebastian, Business Unit Leader Imaging Informatics at Philips. “The capabilities developed by MediReport complement Philips’ strengths in cardiovascular imaging, hemodynamics and enterprise informatics. Together, they are expected to simplify how information moves across cardiac care, enabling a more connected experience for care teams. This would also support Philips’ longer-term direction towards cloud-ready, AI-enabled cardiovascular and integrated diagnostics workflows.” Visit Philips at TCT 2026 to explore innovations in imaging, physiology, procedural guidance and cardiovascular informatics that help care teams access meaningful information and simplify reporting and workflows. [1] Philips Future Health Index 2025: Cardiology Snapshot — Building trust in AI for cardiac care. For further information, please contact: Name Jayme ManiatisPhilips Global External RelationsTel.: +16178948368E-mail: name.here@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment
Philips cardiology informatics at TCT
